Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Other Operating Expenses (2016 - 2025)

Regenxbio (RGNX) has 12 years of Other Operating Expenses data on record, last reported at -$54000.0 in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 93.52% year-over-year to -$54000.0; the TTM value through Dec 2025 reached -$179000.0, up 79.31%, while the annual FY2025 figure was -$179000.0, 79.31% up from the prior year.
  • Other Operating Expenses reached -$54000.0 in Q4 2025 per RGNX's latest filing, up from -$65000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $19.2 million in Q3 2021 and bottomed at -$833000.0 in Q4 2024.
  • Average Other Operating Expenses over 5 years is $6.0 million, with a median of $2.7 million recorded in 2021.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 20008.0% in 2021, then plummeted 144.12% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $15.0 million in 2021, then tumbled by 64.09% to $5.4 million in 2022, then surged by 110.26% to $11.4 million in 2023, then plummeted by 107.34% to -$833000.0 in 2024, then soared by 93.52% to -$54000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were -$54000.0 in Q4 2025, -$65000.0 in Q3 2025, and -$45000.0 in Q2 2025.